



Help protect your newborn from infection


The **BD MAX™ GBS Assay** provides timely and accurate Group B *Streptococcus* screening results to help reduce the risk of GBS disease in newborn babies



The right precautions for mother and child start with the right diagnosis

The BD MAX™ GBS Assay utilizes Lim Broth enrichment to improve detection accuracy of Group B *Streptococcus* versus conventional methods, while enhancing laboratory productivity.

Despite progress made in prevention and treatment, Group B *Streptococcus* (GBS) remains a leading infectious cause of morbidity and mortality among infants in the United States.¹ GBS is naturally carried in some women, and if passed during labor may cause serious health consequences for the newborn.



About 1 in 4 pregnant women carry GBS, the leading cause of bacteremia and meningitis in newborns in the first week of life.²

Protect newborns from GBS disease

- Best practices in prenatal care include testing pregnant women for GBS between 36 to 37 weeks of gestation²
- Health risks to infants with GBS early-onset disease include sepsis, pneumonia and meningitis, while bacteremia, meningitis, or organ or soft-tissue infection are characterizations of GBS late-onset disease²
- Women that test positive for GBS should receive antibiotics during labor to reduce the likelihood of transmission²

References: 1. KPuopolo KM, Lynfield R, Cummings JJ: COMMITTEE ON FETUS AND NEWBORN, COMMITTEE ON INFECTIOUS DISEASES, Management of Infants at Risk for Group B Streptococcal Disease. *Pediatrics* August 2019;144 (2):e20191881.doi:10.1542/peds.2019-1881 2. <https://www.cdc.gov/groupbstrep/about/fast-facts.html> 3. Montague et al., *J Clin Micro* 2008;46:3470-3472 4. Package insert 5. Internal Data

Diagnostic options for antepartum women

	Conventional culture ³	PCR post-enrichment ^{1,4}
Sensitivity	42.3 – 85.5%	92.5 – 100%
Turnaround time	3 – 4 days	1 – 2 days

Lim Broth enrichment followed by identification is recommended by the Centers for Disease Control and Prevention (CDC) to provide accurate identification of GBS in pregnant women.¹

Enhance lab efficiency and productivity with the BD MAX™ GBS Assay

The BD MAX™ GBS Assay, run on the fully-automated, easy-to-use BD MAX™ System, detects GBS DNA in Lim Broth cultures from antepartum women.⁴ The BD MAX™ System accommodates on-demand and batch workflows to meet your laboratory's needs.

approx
1.5
minutes

of hands-on
time per
sample⁵

1
hour

turnaround
time for
1 to 4 samples⁵

2.5
hours

walkaway
convenience
for 24 samples⁵

Let's shape the future of women's health. Together and now.

BD CTGCTV2 Assay • BD Vaginal Panel Assay • BD Onclarity™ HPV Assay • BD MAX™ GBS Assay

For more information about BD's comprehensive diagnostic Women's Health portfolio, please visit [womens-health-solutions.bd.com](https://www.womens-health-solutions.bd.com)



[womens-health-solutions.bd.com](https://www.womens-health-solutions.bd.com)

BD Life Sciences
7 Loveton Circle, Sparks, MD 21152-0999, U.S.
Tel: 1.800.638.8663

BD, the BD Logo, BD MAX and Onclarity are trademarks of Becton, Dickinson and Company or its affiliates. All other trademarks are the property of their respective owners.
© 2023 BD. All rights reserved.
(BD-92312 2052-US-0323 July 2023)